<DOC>
	<DOCNO>NCT01701232</DOCNO>
	<brief_summary>This international multi-center , randomize , control , open-label study investigate pharmacokinetics , pharmacodynamics , efficacy safety BCD-020 ( NN : rituximab , CJSC Biocad ) versus MabThera ( INN : rituximab , F. Hoffmann La Roche , Ltd. ) administer monotherapy patient indolent non-Hodgkin 's lymphoma . Patients randomize receive 375 mg/m² BCD-020 intravenous infusion week 4 week MabThera regimen .</brief_summary>
	<brief_title>Safety Efficacy Study BCD-020 Therapy Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Having sign write informed consent ; Patients ' age 18 year ; Diagnosis CD20positive indolent nonHodgkin lymphoma follow morphological type : Follicular nonHodgkin lymphoma stage IIIV accord Ann Arbor , grade III ; Nodal marginal zone lymphoma stage IIIV accord Ann Arbor ; Splenic marginal zone lymphoma . Life expectancy le 3 month enrollment study ; Morphological immunohistochemical examination tumor ( lymph node biopsy bone marrow biopsy ) within 3 month enrollment study ; Performance status ≤2 ECOG scale ; Hemoglobin &gt; 80 g/l ; leukocyte count ≥ 3.0×109/l less 25×109/l , absolute neutrophil count ≥1.5×109/l , platelet count ≥100×109/l ; Presence least one measurable lesion ; Patient 's ability investigator 's opinion comply protocol procedure ; Willingness patient preserve reproductive function use reliable contraception method ( least two contraception method woman , e.g. , spermicide condom ) . Bulky disease size single lesion 10 cm great diameter ; Secondary transformation highgrade lymphoma ; Other type nonHodgkin lymphomas apart follicular nonHodgkin stage IIIV lymphoma accord Ann Arbor , grade 1,2 ; nodal marginal zone lymphoma stage IIIV accord Ann Arbor ; splenic marginal zone lymphoma . Patients regularly take corticosteroid 1 month precede enrollment study ; Occurrence ( aside NHL ) diseases distort assessment main disease symptom expression ; mask , enhance , modify main disease symptom induce clinical laboratoryinstrumental symptom similar nonHodgkin lymphoma ; Severe resistant hypertension ; Decompensated form heart ( NYHA class ХСН III , IV ) , liver kidney disorder ( creatinine level &gt; 133 µmol/l , AST , ALT , bilirubin level 3 time exceed norm ) except case symptom caused lymphoma ; Decompensated respiratory failure ; Tumor infiltration lung ; Decompensated diabetes mellitus ; Active autoimmune disease ; Ongoing infection require antimicrobial therapy . Usage drug : At time prior enrollment study interferonbased drug monoclonal antibody treatment NHL ; Chemotherapy radiotherapy complete less 21 day prior enrollment study ; Vaccination within 1 week prior enrollment study ; Presence psychiatric disorder include major depressive condition and/or suicidal thought anamnesis opinion investigator may put patient excessive risk influence ability patient fulfill study protocol ; Myocardial infarction le 1 month enrollment study ; Severe CNS PNS dysfunction ; Drug alcohol addiction ; Known HIV , HBV , HCV infection , syphilis ; Known primary secondary immunodeficiency ; Primary CNS lymphoma metastasis CNS ; Known intolerance allergy mouse proteins component study drug , also premedication drug ; Pregnancy lactation ; Prior concomitant malignance except adequately treat basal cell carcinoma situ cervical cancer ; Any restraint impossibility administer study drug via intravenous infusion ; Major surgery within 1 week prior enrollment study ; Simultaneous participation clinical study precede participation study within 3 month prior enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>lymphoma , non-Hodgkin 's</keyword>
</DOC>